Ovarian Reserve in Young Women of Reproductive Age with Crohnʼs Disease

2012 ◽  
Vol 18 (8) ◽  
pp. 1515-1522 ◽  
Author(s):  
Thomas Fréour ◽  
Charline Miossec ◽  
Kalyane Bach-Ngohou ◽  
Thomas Dejoie ◽  
Mathurin Flamant ◽  
...  
2020 ◽  
Vol 18 (2) ◽  
pp. 200-209 ◽  
Author(s):  
Yue Zhao ◽  
Baili Chen ◽  
Yao He ◽  
Shenghong Zhang ◽  
Yun Qiu ◽  
...  

Background/Aims: Crohn’s disease (CD) primarily affects young female adults of reproductive age. Few studies have been conducted on this population’s ovarian reserve status. The aim of study was to investigate potential risk factors associated with low ovarian reserve, as reflected by serum anti-Müllerian hormone (AMH) in women of reproductive age with CD.Methods: This was a case-control study. Cases included 87 patients with established CD, and healthy controls were matched by age, height and weight in a 1:1 ratio. Serum AMH levels were measured by enzyme-linked immunosorbent assay.Results: The average serum AMH level was significantly lower in CD patients than in control group (2.47±2.08 ng/mL vs. 3.87±1.96 ng/mL, respectively, <i>P</i><0.001). Serum AMH levels were comparable between CD patients and control group under 25 years of age (4.41±1.52 ng/mL vs. 3.49±2.10 ng/mL, <i>P</i>=0.06), however, serum AMH levels were significantly lower in CD patients over 25 years of age compared to control group (<i>P</i><0.05). Multivariable analysis showed that an age greater than 25 (odds ratio [OR], 10.03; 95% confidence interval [CI], 1.90–52.93, <i>P</i>=0.007), active disease state (OR, 27.99; 95% CI, 6.13–127.95, <i>P</i><0.001) and thalidomide use (OR, 15.66; 95% CI, 2.22–110.65, <i>P</i>=0.006) were independent risk factors associated with low ovarian reserve (serum AMH levels <2 ng/mL) in CD patients. Conclusions: Ovarian reserve is impaired in young women of reproductive age with CD. Age over 25 and an active disease state were both independently associated with low ovarian reserve. Thalidomide use could result in impaired ovarian reserve.


2008 ◽  
Vol 26 (2) ◽  
pp. 132-137
Author(s):  
P Madhivanan ◽  
K Krupp ◽  
V Chandrasekaran ◽  
C Karat ◽  
A Arun ◽  
...  

2005 ◽  
Vol 54 (5S) ◽  
pp. 34-34
Author(s):  
G. Zh. Bodykov ◽  
А. Т. Raisova ◽  
N. Р. Dolinskaya

The relevance of the problem under study is due to an increase in gynecological morbidity rates, especially an increase in salpingo-oophoritis, characterized by a chronic course, frequent recurrence, severity of consequences and significant impairment of specific functions with persistent disability in young women of reproductive age.


2016 ◽  
Vol 22 ◽  
pp. 4386-4392 ◽  
Author(s):  
Mert Ulas Barut ◽  
Elif Agacayak ◽  
Murat Bozkurt ◽  
Tarık Aksu ◽  
Talip Gul

Medicine ◽  
2021 ◽  
Vol 100 (17) ◽  
pp. e25361
Author(s):  
Shan-Jie Zhou ◽  
Tie-Cheng Sun ◽  
Ling-Li Song ◽  
Ming Yang ◽  
Xin-Ping Sun ◽  
...  

2018 ◽  
Vol 31 (12) ◽  
pp. 785
Author(s):  
Sónia Batista ◽  
Ana Martins da Silva ◽  
Maria José Sá ◽  
Lívia Sousa ◽  
João De Sá ◽  
...  

Multiple sclerosis typically affects young women of reproductive age. Therefore, all healthcare providers involved in the follow-up of multiple sclerosis patients must be prepared to discuss pregnancy and breastfeeding issues, and provide the best possible counselling. However, there are still many doubts and heterogeneous clinical approaches partly due to the lack of consensus and guidelines. Concerning the handling of disease modifying therapies during pregnancy and the postpartum period, uncertainties have been complicated by the increase in recent years of the number of available treatments. This article aims to present the state-of-the-art and provide guidance based on the best level of available evidence and expert opinion regarding the management of multiple sclerosis patients at different stages: pregnancy planning, pregnancy, partum, and the postpartum period.


2019 ◽  
Vol 91 (10) ◽  
pp. 14-18
Author(s):  
O R Grigoryan ◽  
N S Krasnovskaya ◽  
R K Mikheev ◽  
I S Yarovaia ◽  
E N Andreeva ◽  
...  

Aim. To compare ovarian reserve in healthy women of reproductive age - carriers of antithyroid antibodies (ATA) and in healthy women of reproductive age negative for ATA. Materials and methods. 70 healthy women of young reproductive age in the state of euthyroidism (from 18 to 38 years old) were examined. Participants were divided into equal groups (n=35) depending on the status of the presence of antithyroid antibodies (AT-TPO, AT-TG). On the 2nd-4th days of the menstrual cycle, the following markers of the ovarian reserve were determined: serum levels of anti-Müllerian hormone (AMG), inhibin B, FSH, LH, estradiol, testosterone and progesterone, as well as ultrasound parameters - the number of antral follicles and the volume of the ovaries. In addition, to determine the predisposition to premature ovarian failure, an analysis was performed to the number of CGG repeats in the FMR1 gene. Results and discussion. Statistically significantly differs such parameters as the level of estradiol and testosterone, while the differences were not clinically significant. All the parameters evaluated were within the normal range, the main predictors of the ovarian reserve (levels of AMG and inhibin B, the number of antral follicles) remained in the normal range. An increase in the number of repeats of CGG in the FMR1 gene was not detected in any of the participants in the study. Conclusion. In healthy young reproductive age women, the status of ATA does not have a direct effect on the ovarian reserve.


2017 ◽  
Vol 23 (2) ◽  
pp. 72
Author(s):  
E. S. Filippova ◽  
I. F. Kozachenko ◽  
A. G. Bykov ◽  
M. Yu. Bobrov ◽  
L. V. Adamyan

Sign in / Sign up

Export Citation Format

Share Document